Literature DB >> 15726647

Plasmacytoid dendritic cells in acute and chronic hepatitis C virus infection.

Axel Ulsenheimer1, J Tilman Gerlach, Maria-Christina Jung, Norbert Gruener, Martin Wächtler, Markus Backmund, Teresa Santantonio, Winfried Schraut, Malte H J Heeg, Carl A Schirren, Reinhart Zachoval, Gerd R Pape, Helmut M Diepolder.   

Abstract

Chronic evolution of acute hepatitis C (aHC) occurs in more than 80% of patients but can frequently be prevented by early treatment with interferon (IFN)-alpha. Plasmacytoid dendritic cells (pDCs) are the major endogenous IFN-alpha producers, but their role in aHC is unknown. In this study, frequency, phenotype, and pDC function were analyzed in 13 patients with aHC and 32 patients with chronic hepatitis C (cHC) compared with 20 healthy controls, 33 sustained responders to antiviral treatment, 14 patients with acute hepatitis B (aHB), and 21 patients with nonviral inflammatory disease. In aHC, pDCs in the peripheral blood were significantly reduced compared with healthy controls (median, 0.1% vs. 0.36%, P < .0005) and were inversely correlated to alanine aminotransferase levels (r = -0.823; P < .005). Circulating pDCs in aHC were immature, as determined via reduced expression of HLA-DR and CCR7, and produced little amounts of IFN-alpha (median, 3.5 pg/50,000 peripheral blood mononuclear cells [PBMCs] vs. 498.4 pg/50,000 PBMCs in healthy controls; P < .0005). Less pronounced changes were present in cHC (median, 0.17%, 28.0 pg/50,000 PBMCs IFN-alpha, respectively). However, a significantly reduced frequency and IFN-alpha production was also found in self-limited aHB (median 0.1%, 8.6 pg/50,000 PBMCs) and in patients with nonviral inflammatory disease (median 0.19%, 7.5 pg/50,000 PBMCs). In conclusion, in aHC frequency and IFN-alpha-producing capacity of peripheral blood pDCs are dramatically reduced and inversely correlated with the degree of liver inflammation. In cHC there is incomplete recovery of pDC function, which, however, could be solely due to the chronic inflammatory state.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15726647     DOI: 10.1002/hep.20592

Source DB:  PubMed          Journal:  Hepatology        ISSN: 0270-9139            Impact factor:   17.425


  51 in total

1.  Plasmacytoid dendritic cells as guardians in hepatitis C virus-infected liver.

Authors:  Selena M Sagan; Peter Sarnow
Journal:  Proc Natl Acad Sci U S A       Date:  2010-04-19       Impact factor: 11.205

2.  Viral replicative capacity is the primary determinant of lymphocytic choriomeningitis virus persistence and immunosuppression.

Authors:  Andreas Bergthaler; Lukas Flatz; Ahmed N Hegazy; Susan Johnson; Edit Horvath; Max Löhning; Daniel D Pinschewer
Journal:  Proc Natl Acad Sci U S A       Date:  2010-11-22       Impact factor: 11.205

3.  Regulation of host innate immunity by hepatitis C virus: crosstalk between hepatocyte and NK/DC.

Authors:  Sung-Jae Park; Young S Hahn
Journal:  Rev Infect       Date:  2010-07-01

Review 4.  Targeting pattern recognition receptors in cancer immunotherapy.

Authors:  Nadège Goutagny; Yann Estornes; Uzma Hasan; Serge Lebecque; Christophe Caux
Journal:  Target Oncol       Date:  2012-03-08       Impact factor: 4.493

5.  A humanized mouse model to study hepatitis C virus infection, immune response, and liver disease.

Authors:  Michael L Washburn; Moses T Bility; Liguo Zhang; Grigoriy I Kovalev; Adam Buntzman; Jeffery A Frelinger; Walter Barry; Alexander Ploss; Charles M Rice; Lishan Su
Journal:  Gastroenterology       Date:  2011-01-13       Impact factor: 22.682

6.  A self-adjuvanting lipopeptide-based vaccine candidate for the treatment of hepatitis C virus infection.

Authors:  Brendon Y Chua; Emily M Eriksson; Lorena E Brown; Weiguang Zeng; Eric J Gowans; Joseph Torresi; David C Jackson
Journal:  Vaccine       Date:  2008-04-07       Impact factor: 3.641

7.  Tumor necrosis factor receptor 1 expression is upregulated in dendritic cells in patients with chronic HCV who respond to therapy.

Authors:  Raul Cubillas; Katherine Kintner; Frances Phillips; Nitin J Karandikar; Dwain L Thiele; Geri R Brown
Journal:  Hepat Res Treat       Date:  2010-08-03

8.  Impairment of monocyte-derived dendritic cells in idiopathic pulmonary arterial hypertension.

Authors:  Weiyan Wang; Hui Yan; Weiguo Zhu; Yu Cui; Junzhu Chen; Xingxiang Wang; Shan Li; Jianhua Zhu
Journal:  J Clin Immunol       Date:  2009-08-20       Impact factor: 8.317

9.  Impaired plasmacytoid dendritic cell (PDC)-NK cell activity in viremic human immunodeficiency virus infection attributable to impairments in both PDC and NK cell function.

Authors:  Sara J Conry; Kimberly A Milkovich; Nicole L Yonkers; Benigno Rodriguez; Helene B Bernstein; Robert Asaad; Frederick P Heinzel; Magdalena Tary-Lehmann; Michael M Lederman; Donald D Anthony
Journal:  J Virol       Date:  2009-08-19       Impact factor: 5.103

10.  A class C CpG toll-like receptor 9 agonist successfully induces robust interferon-alpha production by plasmacytoid dendritic cells from patients chronically infected with hepatitis C.

Authors:  N A Libri; S J Barker; W M C Rosenberg; A E Semper
Journal:  J Viral Hepat       Date:  2009-02-24       Impact factor: 3.728

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.